Vai al contenuto principale della pagina

Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins / / edited by Ulf Grawunder, Stefan Barth



(Visualizza in formato marc)    (Visualizza in BIBFRAME)

Titolo: Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins / / edited by Ulf Grawunder, Stefan Barth Visualizza cluster
Pubblicazione: Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017
Edizione: 1st ed. 2017.
Descrizione fisica: 1 online resource (XI, 181 p. 57 illus., 39 illus. in color.)
Disciplina: 615.373
Soggetto topico: Pharmacology
Antibodies
Pharmacotherapy
Cancer research
Oncology  
Pharmacology/Toxicology
Cancer Research
Oncology
Persona (resp. second.): GrawunderUlf
BarthStefan
Nota di bibliografia: Includes bibliographical references at the end of each chapters and index.
Nota di contenuto: Chemical Assembly of Antibody-Drug Conjugates -- Pre-clinical evaluation of ADCs delivering highly potent pyrrolobenzodiazepine (PBD) dimers -- Stable and homogeneous drug conjugation by sequential bis-alkylation at disulfide bonds using bis-sulfone reagents -- Calicheamicin antibody-drug conjugates for liquid- and solid tumor indications -- Enzyme-based strategies to generate site-specifically conjugated Antibody Drug Conjugates -- Substance P – Saporin for the Treatment of Intractable Pain -- Recombinant immunotoxins for Chronic Inflammatory Disease -- BL22: A milestone in targeting CD22.
Sommario/riassunto: This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities. The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology.
Titolo autorizzato: Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins  Visualizza cluster
ISBN: 3-319-46877-4
Formato: Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione: Inglese
Record Nr.: 9910253931703321
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Serie: Milestones in Drug Therapy, . 2296-6056